These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 22824630)

  • 1. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.
    Kalayjian RC; Lau B; Mechekano RN; Crane HM; Rodriguez B; Salata RA; Krishnasami Z; Willig JH; Martin JN; Moore RD; Eron JJ; Kitahata MM
    AIDS; 2012 Sep; 26(15):1907-15. PubMed ID: 22824630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care.
    Ganesan A; Krantz EM; Huppler Hullsiek K; Riddle MS; Weintrob AC; Lalani T; Okulicz JF; Landrum M; Agan B; Whitman TJ; Ross MJ; Crum-Cianflone NF;
    HIV Med; 2013 Feb; 14(2):65-76. PubMed ID: 22808988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic kidney disease in Australian Human Immunodeficiency Virus-infected patients: Analysis of the Australian HIV Observational Database.
    Cheung J; Puhr R; Petoumenos K; Cooper DA; Woolley I; Gunathilake M; Raymond N; Varma R; O'Connor CC; Gracey DM
    Nephrology (Carlton); 2018 Aug; 23(8):778-786. PubMed ID: 28703924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting.
    Kaboré NF; Poda A; Zoungrana J; Da O; Ciaffi L; Semdé A; Yaméogo I; Sawadogo AB; Delaporte E; Meda N; Limou S; Cournil A
    BMC Nephrol; 2019 May; 20(1):155. PubMed ID: 31064340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.
    Rossi C; Raboud J; Walmsley S; Cooper C; Antoniou T; Burchell AN; Hull M; Chia J; Hogg RS; Moodie EE; Klein MB;
    BMC Infect Dis; 2017 Apr; 17(1):246. PubMed ID: 28376824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.
    Suzuki S; Nishijima T; Kawasaki Y; Kurosawa T; Mutoh Y; Kikuchi Y; Gatanaga H; Oka S
    AIDS Patient Care STDS; 2017 Mar; 31(3):105-112. PubMed ID: 28282247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
    Mocroft A; Lundgren JD; Ross M; Law M; Reiss P; Kirk O; Smith C; Wentworth D; Neuhaus J; Fux CA; Moranne O; Morlat P; Johnson MA; Ryom L; ; ; ; ;
    PLoS Med; 2015 Mar; 12(3):e1001809. PubMed ID: 25826420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012.
    Morlat P; Vivot A; Vandenhende MA; Dauchy FA; Asselineau J; Déti E; Gerard Y; Lazaro E; Duffau P; Neau D; Bonnet F; Chêne G;
    PLoS One; 2013; 8(6):e66223. PubMed ID: 23776637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
    Rasch MG; Engsig FN; Feldt-Rasmussen B; Kirk O; Kronborg G; Pedersen C; Gerstoft J; Obel N
    Scand J Infect Dis; 2012 Sep; 44(9):689-96. PubMed ID: 22680981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
    Mocroft A; Kirk O; Reiss P; De Wit S; Sedlacek D; Beniowski M; Gatell J; Phillips AN; Ledergerber B; Lundgren JD;
    AIDS; 2010 Jul; 24(11):1667-78. PubMed ID: 20523203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
    Horberg M; Tang B; Towner W; Silverberg M; Bersoff-Matcha S; Hurley L; Chang J; Blank J; Quesenberry C; Klein D
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):62-9. PubMed ID: 19838127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.
    Peters L; Grint D; Lundgren JD; Rockstroh JK; Soriano V; Reiss P; Grzeszczuk A; Sambatakou H; Mocroft A; Kirk O;
    AIDS; 2012 Sep; 26(15):1917-26. PubMed ID: 22781222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.
    Scherzer R; Gandhi M; Estrella MM; Tien PC; Deeks SG; Grunfeld C; Peralta CA; Shlipak MG
    AIDS; 2014 Jun; 28(9):1289-95. PubMed ID: 24922479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of chronic kidney disease in HIV-infected patients.
    Campbell LJ; Ibrahim F; Fisher M; Holt SG; Hendry BM; Post FA
    HIV Med; 2009 Jul; 10(6):329-36. PubMed ID: 19226409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
    Mocroft A; Lundgren JD; Ross M; Fux CA; Reiss P; Moranne O; Morlat P; Monforte Ad; Kirk O; Ryom L;
    Lancet HIV; 2016 Jan; 3(1):e23-32. PubMed ID: 26762990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
    Monteagudo-Chu MO; Chang MH; Fung HB; Bräu N
    J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia.
    Joshi K; Boettiger D; Kerr S; Nishijima T; Van Nguyen K; Ly PS; Lee MP; Kumarasamy N; Wong W; Kantipong P; Cuong DD; Kamarulzaman A; Choi JY; Zhang F; Chaiwarith R; Ng OT; Kiertiburanakul S; Sim BLH; Merati TP; Yunihastuti E; Ditangco R; Ross J; Pujari S
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1209-1216. PubMed ID: 30246898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
    Stöhr W; Reid A; Walker AS; Ssali F; Munderi P; Mambule I; Kityo C; Grosskurth H; Gilks CF; Gibb DM; Hakim J;
    Antivir Ther; 2011; 16(7):1011-20. PubMed ID: 22024517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants and Incidence of Chronic Kidney Disease with Tenofovir- Based Antiretroviral Therapy Regimens: A Cohort Study in HIV-Infected Adults in South China.
    Liu F; Wang Y; Liu H; Chen C; Miao LB; Li ZY; Wang MC; Huang JS; Bao JF
    Curr HIV Res; 2022; 20(3):242-250. PubMed ID: 36111752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.